• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

uPAR 二聚体的晶体结构和细胞功能。

Crystal structure and cellular functions of uPAR dimer.

机构信息

College of Chemistry, Fuzhou University, Fuzhou, 350116, Fujian, China.

College of Biological Science and Engineering, Fuzhou University, 350116, Fuzhou, Fujian, China.

出版信息

Nat Commun. 2022 Mar 29;13(1):1665. doi: 10.1038/s41467-022-29344-y.

DOI:10.1038/s41467-022-29344-y
PMID:35351875
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8964761/
Abstract

Receptor dimerization of urokinase-type plasminogen activator receptor (uPAR) was previously identified at protein level and on cell surface. Recently, a dimeric form of mouse uPAR isoform 2 was proposed to induce kidney disease. Here, we report the crystal structure of human uPAR dimer at 2.96 Å. The structure reveals enormous conformational changes of the dimer compared to the monomeric structure: D1 of uPAR opens up into a large expanded ring that captures a β-hairpin loop of a neighboring uPAR to form an expanded β-sheet, leading to an elongated, highly intertwined dimeric uPAR. Based on the structure, we identify E49P as a mutation promoting dimer formation. The mutation increases receptor binding to the amino terminal fragment of its primary ligand uPA, induces the receptor to distribute to the basal membrane, promotes cell proliferation, and alters cell morphology via β1 integrin signaling. These results reveal the structural basis for uPAR dimerization, its effect on cellular functions, and provide a basis to further study this multifunctional receptor.

摘要

尿激酶型纤溶酶原激活物受体(uPAR)的受体二聚化先前在蛋白质水平和细胞表面得到了鉴定。最近,提出了二聚体形式的小鼠 uPAR 同种型 2 诱导肾脏疾病。在这里,我们报告了人 uPAR 二聚体在 2.96Å 的晶体结构。与单体结构相比,该结构揭示了二聚体的巨大构象变化:uPAR 的 D1 打开成一个大的扩展环,捕获相邻 uPAR 的β发夹环,形成扩展的β-折叠,导致长而高度交织的二聚体 uPAR。基于该结构,我们确定 E49P 是促进二聚体形成的突变。该突变增加了受体与其主要配体 uPA 的氨基末端片段的结合,诱导受体分布到基底膜,促进细胞增殖,并通过β1 整合素信号改变细胞形态。这些结果揭示了 uPAR 二聚化的结构基础、对细胞功能的影响,并为进一步研究这种多功能受体提供了基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a604/8964761/fd5ba5a193b9/41467_2022_29344_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a604/8964761/0a408973a646/41467_2022_29344_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a604/8964761/b305e072c0eb/41467_2022_29344_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a604/8964761/db412f8ccfe4/41467_2022_29344_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a604/8964761/92fd9cf646ca/41467_2022_29344_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a604/8964761/5db414ae8e84/41467_2022_29344_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a604/8964761/fd5ba5a193b9/41467_2022_29344_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a604/8964761/0a408973a646/41467_2022_29344_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a604/8964761/b305e072c0eb/41467_2022_29344_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a604/8964761/db412f8ccfe4/41467_2022_29344_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a604/8964761/92fd9cf646ca/41467_2022_29344_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a604/8964761/5db414ae8e84/41467_2022_29344_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a604/8964761/fd5ba5a193b9/41467_2022_29344_Fig6_HTML.jpg

相似文献

1
Crystal structure and cellular functions of uPAR dimer.uPAR 二聚体的晶体结构和细胞功能。
Nat Commun. 2022 Mar 29;13(1):1665. doi: 10.1038/s41467-022-29344-y.
2
Urokinase-type plasminogen activator receptor (uPAR) ligation induces a raft-localized integrin signaling switch that mediates the hypermotile phenotype of fibrotic fibroblasts.尿激酶型纤溶酶原激活物受体 (uPAR) 配体诱导质膜筏定位的整合素信号开关转换,从而介导纤维母细胞的过度活跃迁移表型。
J Biol Chem. 2014 May 2;289(18):12791-804. doi: 10.1074/jbc.M113.498576. Epub 2014 Mar 18.
3
Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins.肺癌细胞中通过尿激酶和尿激酶受体的信号传导需要与β1整合素相互作用。
J Cell Sci. 2008 Nov 15;121(Pt 22):3747-56. doi: 10.1242/jcs.029769. Epub 2008 Oct 21.
4
Urokinase-type Plasminogen Activator (uPA) Binding to the uPA Receptor (uPAR) Promotes Axonal Regeneration in the Central Nervous System.尿激酶型纤溶酶原激活剂(uPA)与uPA受体(uPAR)结合可促进中枢神经系统中的轴突再生。
J Biol Chem. 2017 Feb 17;292(7):2741-2753. doi: 10.1074/jbc.M116.761650. Epub 2016 Dec 16.
5
Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2.uPAR 的结构域 2 通过β1 整合素和 VEGFR2 调节单链尿激酶介导的血管生成。
Am J Physiol Heart Circ Physiol. 2013 Aug 1;305(3):H305-20. doi: 10.1152/ajpheart.00110.2013. Epub 2013 May 24.
6
Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling.整合素α5β1在尿激酶(uPA)/尿激酶受体(uPAR,CD87)信号传导中的关键作用。
J Biol Chem. 2003 Aug 8;278(32):29863-72. doi: 10.1074/jbc.M304694200. Epub 2003 May 15.
7
Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.拮抗型抗尿激酶型纤溶酶原激活物受体 (uPAR) 抗体可显著抑制 uPAR 介导的细胞信号转导和迁移。
J Biol Chem. 2010 Aug 27;285(35):26878-26888. doi: 10.1074/jbc.M109.077677. Epub 2010 May 25.
8
A Cross Talk between Neuronal Urokinase-type Plasminogen Activator (uPA) and Astrocytic uPA Receptor (uPAR) Promotes Astrocytic Activation and Synaptic Recovery in the Ischemic Brain.神经元型尿激酶型纤溶酶原激活剂(uPA)与星形胶质细胞型uPA受体(uPAR)之间的相互作用促进缺血性脑内星形胶质细胞激活和突触恢复。
J Neurosci. 2017 Oct 25;37(43):10310-10322. doi: 10.1523/JNEUROSCI.1630-17.2017. Epub 2017 Sep 20.
9
Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation.体内选择性阻断 uPA-uPAR 相互作用揭示了其在抑制纤维蛋白相关炎症中的新作用。
Blood. 2010 Sep 2;116(9):1593-603. doi: 10.1182/blood-2010-03-276642. Epub 2010 May 13.
10
ECRG2 regulates cell migration/invasion through urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway.ECRG2通过尿激酶型纤溶酶原激活物受体(uPAR)/β1整合素途径调节细胞迁移/侵袭。
J Biol Chem. 2009 Nov 6;284(45):30897-906. doi: 10.1074/jbc.M109.011213. Epub 2009 Aug 28.

引用本文的文献

1
Endothelial-specific Enhancer as a Cis Element of Regulation by TNF-alpha, IL-1beta, and VEGF.内皮细胞特异性增强子作为 TNF-α、IL-1β 和 VEGF 调节的顺式元件。
Curr Pharm Des. 2024;30(21):1630-1640. doi: 10.2174/0113816128296376240424072322.
2
Role of Soluble Urokinase-Type Plasminogen Activator Receptor in Cardiovascular Disease.可溶性尿激酶型纤溶酶原激活剂受体在心血管疾病中的作用
Curr Cardiol Rep. 2023 Dec;25(12):1797-1810. doi: 10.1007/s11886-023-01991-7. Epub 2023 Nov 10.
3
Cholesterol- and actin-centered view of the plasma membrane: updating the Singer-Nicolson fluid mosaic model to commemorate its 50th anniversary.

本文引用的文献

1
The clinical value of suPAR in diagnosis and prediction for patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.suPAR 在慢性阻塞性肺疾病患者诊断和预测中的临床价值:系统评价和荟萃分析。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620938546. doi: 10.1177/1753466620938546.
2
Senolytic CAR T cells reverse senescence-associated pathologies.衰老细胞清除型 CAR T 细胞可逆转与衰老相关的病理。
Nature. 2020 Jul;583(7814):127-132. doi: 10.1038/s41586-020-2403-9. Epub 2020 Jun 17.
3
Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.
胆固醇和肌动蛋白为中心的细胞膜观点:更新辛格-尼科利森流动镶嵌模型以纪念其 50 周年。
Mol Biol Cell. 2023 May 1;34(5). doi: 10.1091/mbc.E20-12-0809.
4
The Role of the Plasminogen/Plasmin System in Inflammation of the Oral Cavity.纤溶酶原/纤溶酶系统在口腔炎症中的作用。
Cells. 2023 Jan 30;12(3):445. doi: 10.3390/cells12030445.
5
Urokinase System in Pathogenesis of Pulmonary Fibrosis: A Hidden Threat of COVID-19.尿激酶系统在肺纤维化发病机制中的作用:COVID-19 的一个隐藏威胁。
Int J Mol Sci. 2023 Jan 10;24(2):1382. doi: 10.3390/ijms24021382.
可溶性尿激酶型纤溶酶原激活物受体(suPAR)作为新型冠状病毒肺炎患者严重呼吸衰竭的早期预测指标
Crit Care. 2020 Apr 30;24(1):187. doi: 10.1186/s13054-020-02897-4.
4
Soluble Urokinase Receptor and Acute Kidney Injury.可溶性尿激酶型纤溶酶原激活物受体与急性肾损伤
N Engl J Med. 2020 Jan 30;382(5):416-426. doi: 10.1056/NEJMoa1911481.
5
Podocin and uPAR are good biomarkers in cases of Focal and segmental glomerulosclerosis in pediatric renal biopsies.足细胞和尿激酶型纤溶酶原激活物受体(uPAR)是儿童肾活检局灶节段性肾小球硬化的良好生物标志物。
PLoS One. 2019 Jun 12;14(6):e0217569. doi: 10.1371/journal.pone.0217569. eCollection 2019.
6
Did evolution create a flexible ligand-binding cavity in the urokinase receptor through deletion of a plesiotypic disulfide bond?通过删除一个古老的二硫键,进化是否在尿激酶受体中创造了一个灵活的配体结合腔?
J Biol Chem. 2019 May 3;294(18):7403-7418. doi: 10.1074/jbc.RA119.007847. Epub 2019 Mar 20.
7
Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.可溶性尿激酶型纤溶酶原激活物受体可预测 1 型糖尿病患者的心血管事件、肾功能下降和死亡。
Diabetes Care. 2019 Jun;42(6):1112-1119. doi: 10.2337/dc18-1427. Epub 2019 Mar 18.
8
uPAR isoform 2 forms a dimer and induces severe kidney disease in mice.uPAR 同种型 2 形成二聚体并在小鼠中诱导严重肾脏疾病。
J Clin Invest. 2019 Apr 2;129(5):1946-1959. doi: 10.1172/JCI124793.
9
SuPAR, an emerging biomarker in kidney and inflammatory diseases.尿可溶性髓系细胞触发受体-1,肾脏病和炎症性疾病的一个新兴生物标志物。
Postgrad Med J. 2018 Sep;94(1115):517-524. doi: 10.1136/postgradmedj-2018-135839. Epub 2018 Sep 3.
10
Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus.可溶性尿激酶型纤溶酶原激活物受体 (suPAR) 可预测 2 型糖尿病高危患者的微量白蛋白尿。
Sci Rep. 2017 Jan 16;7:40627. doi: 10.1038/srep40627.